General Hospital of Syros
- Address
- Georgiou Papandreou 2, Ermoupoli, 84100 Syros, Greece
Analytical, Diagnostic and Therapeutic Techniques and Equipment
The General Hospital of Syros is advancing diagnostic and therapeutic technologies to enhance care for patients with Community-acquired pneumonia and sepsis. Trials aim to test biomarker‑guided antibiotic regimens that could reduce disease progression.
- Biomarker‑guided clarithromycin therapy for early pneumonia management
- Single‑dose meropenem administration based on PSP levels
- Integration of suPAR and NEWS2 scores to tailor treatment
These initiatives position the site at the forefront of innovative infection management in Europe.
Pathological Conditions, Signs and Symptoms
Research concentrates on early detection of clinical indicators that signal a shift toward severe infection, employing bedside scores and biomarkers to guide rapid therapeutic decisions.
- qSOFA‑driven treatment pathways for suspected sepsis
- Utilization of NEWS2 scoring to identify high‑risk patients
- Evaluation of PSP as a prognostic marker for infection outcomes
By focusing on these predictive tools, the hospital aims to improve timely intervention and patient survival.
Respiratory Tract Diseases
Focused on respiratory infections, especially Community-acquired pneumonia, the center evaluates adjunctive therapies such as clarithromycin and meropenem to curb disease progression and reduce mortality.
- Adjunctive clarithromycin to prevent sepsis in pneumonia patients
- Early meropenem dosing guided by PSP and clinical scores
- Biomarker‑driven strategies to personalize antimicrobial treatment
The program underscores the hospital’s commitment to advancing respiratory care through evidence‑based interventions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 173 other sites in Greece
Therapeutic Area Benchmark — Greece
Select a therapeutic area to compare against other sites in Greece.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Greece
Market Share
Country: Greece
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in General Hospital of Syros
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Biomarker-Guided Early Clarithromycin Administration to Prevent Sepsis Progression in Community-Acquired Pneumonia: A Randomized Controlled Trial | Elliniko Institouto Meletis Tis Sipsis | Phase III | Recruiting | Feb 2024 | — |
IMP list
lock Showing 1 of 3 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Clarithromycin | 1 | Unknown | 2024-02-12 | 2024-02-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.